Centinel Spine wins Australian clearance for Stalif L implant

Centinel Spine said yesterday it won Australian Therapeutic Goods Administration clearance for its Stalif L no-profile lateral lumbar integrated interbody system. Centinel Spine touts the Stalif L as the only lateral device to offer a no-profile, compressive lag fixation device with proprietary anti-backout technology and 12-degrees of lordosis, as well as a large chamber for bone graft to support fusion. “This clearance expands our International No-Profile, Integrated Interbody market. Stalif has enjoyed a long successful history in Australia and now Stalif L exemplifies our continued commitment to being the gold standard in Integrated Interbody devices.  We are excited to bring the Stalif advantage to minimally-invasive spinal fusion surgery in Australia,” CEO John Viscogliosi said in a press release. “Orthotech is proud to represent Centinel Spine in Australia.  We are excited to receive the Stalif L clearance enabling us to provide this innovative technology to our surgeon customers and their spine surgery patients. The entire Stalif product portfolio, including the new Stalif L, and the Ti-Active technology, a texturized, titanium coating, allows our surgeon customers to offer their patients the most up-to-date spinal technologies with a heritage of more than 25 years of proven clinical success as a treatment for degenerative spinal pathologies,” Orthotech Orthopaedics Holdings managing director Sam Scott-Young said in a prepared statement....
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Regulatory/Compliance Spinal Centinel Spine LLC Source Type: news